Jayaraman Krishnaraj

Dr. Jayaraman Krishnaraj

Laboratory of Fundamental Oncology, National Cancer Center Research Institute, Tokyo, Japan
orcid
Homo sapiens

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
ABAbdul Basit Baba
Abdul Basit Baba
JKJaganathan Kowshik
Jaganathan Kowshik
JKJayaraman Krishnaraj
Jayaraman Krishnaraj
JSJosephraj Sophia
Josephraj Sophia
MDMadhulika Dixit
Madhulika Dixit
SNSiddavaram Nagini
Siddavaram Nagini

28 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JKJayaraman Krishnaraj
Jayaraman Krishnaraj
TYTatsuki Yamamoto
Tatsuki Yamamoto
Rieko OhkiRieko Ohki
Rieko Ohki
Resistance to chemoradiotherapy is the main cause of cancer treatment failure. Cancer cells, especially cancer stem cells, utilize innate cytoprotective mechanisms to protect themselves from the adverse effects of chemoradiotherapy. Here, we describe a few such mechanisms: DNA damage response (DDR), immediate early response gene 5 (IER5)/heat-shock factor 1 (HSF1) pathway, and p21/nuclear factor erythroid 2–related factor 2 (NRF2) pathway, which are regulated by the tumour suppressor p53. Upon DNA damage caused during chemoradiotherapy, p53 is recruited to the sites of DNA damage and activates various DNA repair enzymes including GADD45A, p53R2, DDB2 to repair damaged-DNA in cancer cells. In addition, the p53-IER5-HSF1 pathway protects cancer cells from proteomic stress and maintains cellular proteostasis. Further, the p53-p21-NRF2 pathway induces production of antioxidants and multidrug resistance-associated proteins to protect cancer cells from therapy-induced oxidative stress and to promote effusion of drugs from the cells. This review summarises possible roles of these p53-regulated cytoprotective mechanisms in the resistance to chemoradiotherapy.

6 February 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MTMasahiro Takikawa
Masahiro Takikawa
ANAiri Nakano
Airi Nakano
JKJayaraman Krishnaraj
Jayaraman Krishnaraj
YTYuko Tabata
Yuko Tabata
YWYuzo Watanabe
Yuzo Watanabe
Rieko OhkiRieko Ohki
Rieko Ohki
Tumor progression is suppressed by inherent cellular mechanisms such as apoptosis. The p53 tumor suppressor gene is the most commonly mutated gene in human cancer and plays a pivotal role in tumor suppression. RPRM is a target gene of p53 known to be involved in tumor suppression, but its molecular function has remained elusive. Here, we report that Reprimo (the protein product of RPRM ) is secreted and extrinsically induces apoptosis in recipient cells. We identified FAT1, FAT4, CELSR1, CELSR2, and CELSR3, members of the protocadherin family, as receptors for Reprimo. Subsequent analyses revealed that Reprimo acts upstream of the Hippo–YAP/TAZ–p73 axis and induces apoptosis by transactivating various proapoptotic genes. In vivo analyses further support the tumor-suppressive effects of secreted Reprimo. These findings identify the p53–Reprimo–Hippo–YAP/TAZ–p73 axis as an extrinsic apoptosis pathway that plays a crucial role in tumor suppression. Our finding of the innate tumor eliminator Reprimo and the downstream pathway offers a promising avenue for the pharmacological treatment of cancer.

1 May 2017 in Toxicology Letters
Verified
Journal Article
Closed access
JKJayaraman Krishnaraj
Jayaraman Krishnaraj
JKJaganathan Kowshik
Jaganathan Kowshik
RSRobin Sebastian
Robin Sebastian
SRSathees C. Raghavan
Sathees C. Raghavan
SNSiddavaram Nagini
Siddavaram Nagini

22 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
WKWalied Kamel
Walied Kamel
JKJayaraman Krishnaraj
Jayaraman Krishnaraj
Rieko OhkiRieko Ohki
Rieko Ohki
Pleckstrin homology-like domain family A, member 3 (PHLDA3) is a p53-regulated tumor suppressor protein that suppresses AKT-mediated survival and oncogenic signaling. The PHLDA3 gene has garnered significant attention due to its multifaceted roles in tumorigenesis, metastasis, and invasion. This review explores the complex interactions between PHLDA3 and key cellular processes involved in cancer, emphasizing its regulatory mechanisms and clinical relevance. PHLDA3 has been found to be a critical regulator of metastatic pathways, particularly through its influence on the epithelial–mesenchymal transition (EMT) and in cellular invasion. Its interactions with pivotal signaling pathways, such as the Phosphoinositide 3-kinases/Protein kinase B (PI3K/AKT), p53, and Wnt/β-catenin pathways, highlight its multifunctional roles in various cancer types. Additionally, we discuss the potential of PHLDA3 as both a prognostic biomarker and a therapeutic target, offering new insights into its potential in treating advanced-stage malignancies. This review provides a detailed analysis of the role of PHLDA3 in cancer progression, including metastasis and invasion, underscoring its therapeutic potential.

3 December 2018 in Journal of Toxicology and Environmental Health, Part A
Verified
Journal Article
Closed access
JKJayaraman Krishnaraj
Jayaraman Krishnaraj
ABAbdul Basit Baba
Abdul Basit Baba
PVPeriasamy Viswanathan
Periasamy Viswanathan
VVVeeran Veeravarmal
Veeran Veeravarmal
VBViswalingam Balasubramanian
Viswalingam Balasubramanian
SNSiddavaram Nagini
Siddavaram Nagini
Substantial evidence has established the negative impact of inhalation exposure to welding fumes on respiratory functions. The aim of the present study was to investigate the effect of welding fume inhalation on expression of molecules that function as sensors, transducers and effectors of DNA damage response (DDR) in the respiratory tract of male Sprague-Dawley rats. Animals were exposed to 50 mg/m3 stainless steel welding fumes for 1 h/d for 4, 8, and 12 weeks, respectively. Histological examination demonstrated preneoplastic changes in trachea and bronchi with focal atelectasis and accumulation of chromium (Cr) in the lungs. This was associated with elevated levels of DNA damage markers (8-oxodG, γH2AX), ATM phosphorylation, cell cycle arrest, apoptosis induction, activation of homologous recombination (HR), non-homologous end joining (NHEJ), and Nrf2 signaling, as well as altered expression of noncoding RNAs (ncRNAs). However, after 12 weeks of exposure, DDR was compromised as reflected by resumption of the cell cycle, repair inhibition, and failure of apoptosis. Data demonstrate that exposure to welding fumes influences two crucial layers of DDR regulation, phosphorylation of key proteins in NHEJ and HR, as well as the ncRNAs that epigenetically modulate DDR. Evidence indicates that marked DNA damage coupled with non-productive DNA repair and apoptosis avoidance may be involved in neoplastic transformation.